in 2011, pharmaceutical manufacturing revenues increased by 29.4 percent, higher than the 27.2% growth in overall industrial enterprises; gross profit increased by 23.5%, lower than the 25.3% growth of industrial enterprises (excluding bulk drugs, pharmaceutical manufacturing revenues and profits year on year increase of 31.3%, 24%). By the macroeconomic impact of the growth of revenue and profits of industrial enterprises showed a gradually declining trend throughout the year, while the demand for rigid pharmaceutical manufacturing, and by the macroeconomic impact of a smaller, in addition to good outside income performance, full-year profit growth is low after the high.

benefit to maintain a rapid growth in demand based medicine cheap tender will be corrected, some of the lower raw material costs, in 2012 the pharmaceutical manufacturing industry revenue growth may be lower than in 2011, but profit growth speed will be higher than in 2011.

pharmaceutical industry is a change the situation in all respects with may be the opportunity of developing, but that is such a multi-level market, the reform will not be smooth . Has been in the past three years, the basic medical insurance for the implementation of faster, but also many problems – has been widely criticized hospital to drugs to support medical model makes “your doctor” can not be alleviated, the implementation of good intentions and the subsequent benefits of the basic drug system allocation of the problem and is difficult to place the compensation.

pay reform in exploration: the government departments to learn from advanced international payment system, such as Medicare to explore the total prepaid outpatient co-ordinate pay on a per capita, inpatient and outpatient illness disease pay, pay in the first batch of 40 health care reform in key cities to explore the Chinese health care payment system reform in 2011. From international experience, the payment system reform to promote rigid demand release, improve capital efficiency, but does not affect the pharmaceutical and drug consumption expenditure.

The

reform of drug prices is: industry reshuffle accelerate, innovation and differentiation is the final road of the pharmaceutical companies.

from November 2010 to the present, the pharmaceutical sector has gone Bear 18. 2011, pharmaceutical manufacturing (excluding bulk drugs) revenue and profit growth data is not bad, but there are a number of profit 30%, or even 40-50% of the rapid growth of the company, although no-expected, but in 2011 the environment it is not easy. Fell down the factors of the overall market valuation, as well as market sentiment of pessimism and the discount allowed on the trend of policy is not clear.

the long term, the focus and differentiation of the pharmaceutical industry is still a big trend, with the R & D strengths variety advantage, brand and channel advantage will gradually win, investments in these varieties will receive long-term interests.